Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBLG NASDAQ:BTCY NASDAQ:FEMY NASDAQ:IRIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBLGBone Biologics$2.48-3.5%$2.31$1.95▼$13.80$4.61M0.75148,509 shs33,951 shsBTCYBiotricity$0.64+3.2%$0.59$0.22▼$0.83$17.11M1.1238,066 shs20,235 shsFEMYFemasys$0.70-5.7%$0.50$0.31▼$1.80$24.28M-2.6411.85 million shs27.49 million shsIRIXIRIDEX$1.04-1.0%$1.21$0.78▼$1.95$17.67M0.5971,293 shs25,569 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBLGBone Biologics-3.50%+2.06%+17.54%-13.29%-78.01%BTCYBiotricity+3.23%+8.29%+1.91%+47.06%+190.91%FEMYFemasys-5.67%+14.79%+97.11%-20.10%-42.84%IRIXIRIDEX-0.95%0.00%-19.38%-17.46%-34.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBLGBone Biologics$2.48-3.5%$2.31$1.95▼$13.80$4.61M0.75148,509 shs33,951 shsBTCYBiotricity$0.64+3.2%$0.59$0.22▼$0.83$17.11M1.1238,066 shs20,235 shsFEMYFemasys$0.70-5.7%$0.50$0.31▼$1.80$24.28M-2.6411.85 million shs27.49 million shsIRIXIRIDEX$1.04-1.0%$1.21$0.78▼$1.95$17.67M0.5971,293 shs25,569 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBLGBone Biologics-3.50%+2.06%+17.54%-13.29%-78.01%BTCYBiotricity+3.23%+8.29%+1.91%+47.06%+190.91%FEMYFemasys-5.67%+14.79%+97.11%-20.10%-42.84%IRIXIRIDEX-0.95%0.00%-19.38%-17.46%-34.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBLGBone Biologics 1.00SellN/AN/ABTCYBiotricity 2.00HoldN/AN/AFEMYFemasys 2.50Moderate Buy$7.33943.00% UpsideIRIXIRIDEX 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BBLG, IRIX, BTCY, and FEMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025BBLGBone BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025FEMYFemasysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025IRIXIRIDEXWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025BBLGBone BiologicsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)9/27/2025FEMYFemasysWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025IRIXIRIDEXWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)8/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBLGBone BiologicsN/AN/AN/AN/A$8.39 per shareN/ABTCYBiotricity$12.06M1.42N/AN/A($1.30) per share-0.49FEMYFemasys$1.89M12.14N/AN/A$0.10 per share7.03IRIXIRIDEX$49.74M0.36N/AN/A$0.13 per share8.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBLGBone Biologics-$4.11MN/A0.00N/AN/AN/A-100.58%-93.31%11/13/2025 (Estimated)BTCYBiotricity-$14.09M-$0.21N/A∞N/A-80.42%N/A-188.47%11/13/2025 (Estimated)FEMYFemasys-$18.82M-$0.86N/AN/AN/A-1,113.72%-713.74%-152.60%11/11/2025 (Estimated)IRIXIRIDEX-$8.91M-$0.33N/A∞N/A-10.95%-386.93%-17.42%11/11/2025 (Estimated)Latest BBLG, IRIX, BTCY, and FEMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/13/2025N/ABBLGBone Biologics-$1.23N/AN/AN/AN/AN/A11/13/2025N/ABTCYBiotricity-$0.08N/AN/AN/A$3.90 millionN/A11/11/2025N/AFEMYFemasys-$0.12N/AN/AN/AN/AN/A8/14/2025Q2 2025BBLGBone Biologics-$0.58-$1.33-$0.75-$1.33N/AN/A8/12/2025Q2 2025IRIXIRIDEX-$0.09-$0.06+$0.03-$0.06$13.10 million$13.57 million8/8/2025Q2 2025FEMYFemasys-$0.18-$0.16+$0.02-$0.16$0.80 million$0.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBLGBone BiologicsN/AN/AN/AN/AN/ABTCYBiotricityN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBLGBone BiologicsN/A17.2517.25BTCYBiotricityN/A0.230.10FEMYFemasys0.030.890.41IRIXIRIDEX62.291.961.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBLGBone Biologics34.30%BTCYBiotricity3.89%FEMYFemasys65.27%IRIXIRIDEX20.10%Insider OwnershipCompanyInsider OwnershipBBLGBone Biologics6.10%BTCYBiotricity10.10%FEMYFemasys11.54%IRIXIRIDEX7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBLGBone Biologics21.80 million1.69 millionNot OptionableBTCYBiotricity4026.73 million22.08 millionOptionableFEMYFemasys3032.58 million28.82 millionNot OptionableIRIXIRIDEX12016.99 million15.74 millionOptionableBBLG, IRIX, BTCY, and FEMY HeadlinesRecent News About These CompaniesHead to Head Survey: IRIDEX (NASDAQ:IRIX) and Micro Imaging Technology (OTCMKTS:MMTC)October 17 at 2:09 AM | americanbankingnews.comIridex regains compliance with Nasdaq listing requirementsSeptember 9, 2025 | msn.comIridex regains Nasdaq listing complianceSeptember 9, 2025 | msn.comIridex Corporation Receives Formal Notification of Nasdaq Listing ComplianceSeptember 9, 2025 | globenewswire.comWilliam Moore Purchases 12,024 Shares of IRIDEX (NASDAQ:IRIX) StockAugust 20, 2025 | insidertrades.comIRIDEX Corporation (NASDAQ:IRIX) Q2 2025 Earnings Call TranscriptAugust 13, 2025 | insidermonkey.comIridex Reports 7 Percent Q2 Revenue GainAugust 13, 2025 | aol.comAIridex Reports Revenue Growth and Expense Reduction in Q2 2025August 13, 2025 | msn.comIRIDEX Corporation (IRIX) Q2 2025 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comIridex Reports Second Quarter 2025 Financial ResultsAugust 12, 2025 | globenewswire.comIRIDEX Corporation (IRIX) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comIridex Announces First Patient Enrolled in an Independent Landmark Investigator-Led UK Study Evaluating MicroPulse® Technology as an Adjunct to anti-VEGF Therapy for Diabetic Macular EdemaJune 24, 2025 | globenewswire.comIRIDEX expands stock plan and amends charterJune 15, 2025 | investing.comIRIDEX Stock Price HistoryJune 2, 2025 | investing.comThursday’s Insider Activity: Top Buys and Sells in US StocksMay 30, 2025 | investing.comIRIDEX Faces Nasdaq Delisting Over Equity ShortfallMay 21, 2025 | investing.comIRIDEX Corporation (NASDAQ:IRIX) Q1 2025 Earnings Call TranscriptMay 16, 2025 | insidermonkey.comIRIDEX Corp.May 14, 2025 | money.usnews.comIRIDEX Corporation, Inc. (IRIX) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comIridex Reports First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBBLG, IRIX, BTCY, and FEMY Company DescriptionsBone Biologics NASDAQ:BBLG$2.48 -0.09 (-3.50%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$2.42 -0.06 (-2.42%) As of 10/17/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.Biotricity NASDAQ:BTCY$0.64 +0.02 (+3.23%) As of 10/17/2025 03:58 PM EasternBiotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.Femasys NASDAQ:FEMY$0.70 -0.04 (-5.67%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$0.61 -0.10 (-13.81%) As of 10/17/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.IRIDEX NASDAQ:IRIX$1.04 -0.01 (-0.95%) Closing price 10/17/2025 03:50 PM EasternExtended Trading$1.06 +0.02 (+1.83%) As of 10/17/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
